<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> predisposes to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the value of endoscopic surveillance in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> has been debated because of the low incidence of esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, high inter-observer and sampling-dependent variation in the histologic staging of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> make clinical risk assessment problematic </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we developed a 3-tiered risk stratification strategy, based on systematically selected epigenetic and clinical parameters, to improve <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> surveillance efficiency </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND FINDINGS: We defined high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> as endpoint of progression, and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> progressor patients as <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> patients with either no <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> who later developed high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>We analyzed 4 epigenetic and 3 clinical parameters in 118 <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> tissues obtained from 35 progressor and 27 non-progressor <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> patients from Baltimore Veterans Affairs Maryland Health Care Systems and Mayo Clinic </plain></SENT>
<SENT sid="6" pm="."><plain>Based on 2-year and 4-year prediction models using linear discriminant analysis (area under the receiver-operator characteristic (ROC) curve: 0.8386 and 0.7910, respectively), <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> specimens were stratified into high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups </plain></SENT>
<SENT sid="7" pm="."><plain>This 3-tiered stratification method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model </plain></SENT>
<SENT sid="8" pm="."><plain>Progression-free survivals differed significantly among the 3 risk groups, with p = 0.0022 (HR vs. IR) and p&lt;0.0001 (HR or IR vs. LR) </plain></SENT>
<SENT sid="9" pm="."><plain>Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction accuracy </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: This 3-tiered risk stratification strategy has the potential to exert a profound impact on <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> surveillance accuracy and efficiency </plain></SENT>
</text></document>